An observational study in Pneumonia, Viral and COVID-19 Pneumonia, sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.
Sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The AI-based system designed to process chest computed tomography (CT) aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4).
The retrospective study aims to demonstrate the clinical validation of the AI-based system. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined to provide evidence about the clinical efficacy of the AI-based system.
The hypothesis is that the measures of clinical validation of the AI-based system differ by no more than 8% from those declared by the manufacturer.
The AI-based system designed to process chest CT aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4).
This retrospective clinical study will provide the clinical validation of the AI-based system to analyze chest CT images and identify pathological patterns associated with interstitial changes in pneumonia. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined and compared with values declared by the manufacturer to provide evidence about the clinical efficacy of the AI-based system.
The first stage of clinical validation is the collection of a verified labeled dataset. For this purpose, the dataset is collected, labeled, and verified by a research group. The verified dataset should include chest CT images without infiltrative and interstitial lung changes characteristic of viral pneumonia, including COVID-19-associated (CT-0) and chest CT images of all degrees of lung involvement CT-1 (≤25%), CT-2 (25-50%), CT-3 (50-75%), CT-4 (≥75%) [1]. Forming the verified dataset will allow reliable conclusions to be drawn upon completion of the clinical validation. The verified dataset must include a sufficient volume of chest CT images. The verified dataset must be de-identified to ensure the safety of patient personal data.
The second stage of the clinical validation is assessing AI-based system performance by experts. For that purpose, the AI software is analyzed to identify radiological signs of viral pneumonia. Then an examination is made of the correctness of the quantitative assessment of lung damage associated with interstitial changes in pneumonia. The evaluation of both the ability to correctly identify signs of lung damage and to quantify the identified changes is carried out on the same verified dataset.
The third stage of clinical validation is the calculation of clinical efficacy metrics (accuracy, sensitivity, specificity, area under the ROC-curve (AUROC) of the AI-based system by testing it on a verified data set. Testing of the hypothesis to verify the main diagnostic characteristics (sensitivity and specificity) declared by the manufacturer is planned by constructing a two-sided 95% confidence interval (CI), which should not differ by more than 8% from the declared values of 95% and 97%, respectively. Those. the lower limit of the 95% CI for sensitivity should not cross the 87% threshold, and the lower limit of the 95% CI for specificity should not cross the 89% threshold.
All stages of the clinical trial must be under the control of the Principal Investigator.
Randomization of images is not provided in this clinical study, because All CT images will be assessed by the research group and AI software. Also, this design does not involve blinding or masking of the research team. The evaluation of CT images by experts and the software is carried out independently, i.e. the results of each party's assessment are not known to the other party in advance.
156 studies on the registry are indexed under Pneumonia, Viral; 12 are open to participants now.
This study's planned enrollment of 563 is above the median of 233 across 55 observational studies indexed under Pneumonia, Viral.
Browse Pneumonia, Viral studies →Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults (patients over 18 years of age) who were referred for a chest CT study by a physician in case of suspicion or monitoring the effectiveness of treatment of diseases manifested by changes in the pulmonary parenchyma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General
For group Normal
a. Patients who do not contain COVID-19-related CT patterns;
For groups Mild, Moderate, Severe, and Critical
Exclusion Criteria:
CT-0. Not consistent with pneumonia (including COVID-19). \[1,2\] Enrollment number: 95
Diagnostic Test: Medical software (AI-based system)
СT-1. Ground glass opacities. Pulmonary parenchymal involvement =\<25% OR absence CT signs in typical clinical manifestations and relevant epidemiological history \[1,2\]. Enrollment number: 117
Diagnostic Test: Medical software (AI-based system)
CT-2. Ground glass opacities. Pulmonary parenchymal involvement 25-50% \[1,2\]. Enrollment number: 117
Diagnostic Test: Medical software (AI-based system)
CT-3. Ground glass opacities. Pulmonary consolidation. Pulmonary parenchymal involvement 50-75%. Lung involvement increased in 24-48 hours by 50% in respiratory impairment per follow-up studies \[1,2\]. Enrollment number: 117
Diagnostic Test: Medical software (AI-based system)
CT-4. Diffuse ground glass opacities with consolidations and reticular changes. Hydrothorax (bilateral, more on the left). Pulmonary parenchymal involvement \>=75% \[1,2\]. Enrollment number: 117
Diagnostic Test: Medical software (AI-based system)
Retrospective analysis of chest CT images with medical software (AI-based system)
Accuracy
The ability of an AI-based system to produce the correct result relative to the total number of trials
Time frame: Upon completion, up to 1 year
Sensitivity
Effectiveness of the AI-based system to correctly identifies patients with the suspected viral pneumonia related lung changes
Time frame: Upon completion, up to 1 year
Specificity
Effectiveness of the AI-based system to correctly identifies across a range of available measurements patients that do not have the suspected viral pneumonia related lung changes
Time frame: Upon completion, up to 1 year
AUC ROC
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI-based system in prediction of suspected viral pneumonia related lung changes
Time frame: Upon completion, up to 1 year
Approximate volume of affected lung tissue
Approximate volume of affected lung tissue - quantitative characteristics of lung damage volume in percent (%): separately for left lung, right lung and total percentage of damage
Time frame: Time Frame: Upon completion, up to 1 year
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department